Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetStock SplitAnalyst Ratings
Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 to $10.
Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 to $10.